Thymus therapy for cancer? A criteria-based, systematic review

European Journal of Cancer Part A

Volumn 33, Issue 4, 1997, Pages 531-535

  Ernst, E ^a  

^a UNIVERSITY OF EXETER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DRG ZELLMEDIN THYMUS; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; NEYTUMORIN; THYMOSIN ALPHA1; THYMOSIN FRACTION 5; THYMOSTIMULIN; THYMUS EXTRACT; UNCLASSIFIED DRUG; VITAMIN B COMPLEX;

ALTERNATIVE MEDICINE; BREAST CARCINOMA; CELL MATURATION; CELLULAR IMMUNITY; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; HODGKIN DISEASE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEYTHYMUN; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SINGLE BLIND PROCEDURE; T LYMPHOCYTE; THYMUS;

HUMANS; MEDLINE; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; THYMUS EXTRACTS; TISSUE THERAPY; TREATMENT OUTCOME; UNITED STATES;

EID: 0030943874     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00475-3     Document Type: Review

References (29)

1. Downer SM, Cody MM, McCluskey P, et al. Pursuit and practice of complementary therapies by cancer patients receiving conventional treatment. Br Med J 1994, 309, 86-89.
2. Cassileth BR, Lusk EJ, Strouse TB, Bodenheimer BJ. Contemporary unorthodox treatments in cancer medicine. Ann Intern Med 1984, 101, 105-112.
3. Ernst E. Complementary cancer treatments, hope or hazard? Clin Oncol 1995, 7, 259-263.
4. Shoham J, Cohen M. Thymic hormonal activity on peripheral blood lymphocytes in vitro. Int J Immunopharmacol 1983, 5, 523-532.
5. Cohen MH, Chretien PB, Ihde DC, et al. Thymosin fraction V and intensive combination chemotherapy - prolonging the survival of patients with small-cell lung cancer. JAMA 1979, 241, 1813-1815.
6. Luzi G, Tropea F, Siminara R, et al. Clinical and immunological evaluation in non-resectable lung cancer patients treated with thymostimulin. Serono Symposia Publications 1984, 16, 309-320.
7. Schulof RS, Lloyd MJ, Cleary PA, et al. A randomized trial to evaluate the immunorestorative properties of synthetic thymo-sin-alpha;l in patients with lung cancer. J Biol Resp Modif 1985, 4, 147-158.
8. R k in Vergleich zu einem Placebo In G Braun GmbH (Hrsg). Biological Response Modifiers, in Klinik und Praxis, Band 10 Braun, Karlsruhe S, 1986, 60-71.
9. Trutwin H. Doppelblindstudie über den Immunstatus bei Mammakarzinom-Patientinnen mit peroral appliziertem Thymus-Extrakt. Erfahrungsheilkunde 1987, 36, 94-100.
10. Chisesi T, Capnist G, Rancan L, Pellizzari G, Vespignani M. The effect of thymic substances on T circulating cells of patients treated for Hodgkin's disease. J Biol Regul Homeost Agents 1988, 2, 193-198.
11. Iaffaioli RV, Frasci G, Tortora G, et al. Effect of thymic extract "thymostimulin" on the incidence of infections and myelotoxicity during adjuvant chemotherapy for breast cancer. Thymus 1988, 12, 69-75.
12. Liberati AM, Ballatori E, Fizzotti M, et al. A randomized trial to evaluate the immunorestorative properties of thymostimulin in patients with Hodgkin's disease in complete remission. Cancer Immunol Immunother 1988, 26, 87-93.
13. Macchiarini P, Danesi R, Del-Tacca M, Angeletti CA. Effects of thymostimulin on chemotherapy-induced toxicity and longterm survival in small cell lung cancer patients. Anticancer Res 1989, 9, 193-196.
14. Canovas-Fernandez A, Alonso-Alonso J, Gonzalez-de-Zarate P, Garcia-Masdevall MD, Rinon-Martinez-Gallo M, Aguirre-Errasti C. The use of thymostimulin in lymphoma and myeloma patients. Ann Int Med 1991, 8, 69-73.
15. Pavesi L. Italian Cooperative Trials Group. Fluorouracil (F), with or without high dose folinic acid (HDFA) plus Epirubicin (E) and Cyclophosphamide (C): FEC versus HDFA-FEC plus or minus Thymostimulin (TS) in metastatic breast cancer: results of a multicentre study. Eur J Cancer 1993, 29A, S77.
16. Mustacchi G, Pavesi L, Milani S. High doses of folinic acid and fluorouracil plus or minus thymostimulin for the treatment of metastatic colorectal cancer: results of a randomised muticenter clinical trial. Anticancer Res 1994, 14, 617-619.
17. Federico M, Gobbi PG. Effects of thymostimulin with combination chemotherapy in patients with aggressive non-Hodgkin's lymphoma. Am J Clin Oncol 1995, 18, 8-14.
18. Marcos C, Quirce S, Lazaro M, Igea JM, Cuesta J, Losada E. Severe anaphylactic reactions to thymostimulin. Allergy 1991, 46, 235-237.
19. Aleksandrowicz J, Turowski G, Czarnecki J, Szmigiel Z, Cybulski L, Skotnicki AB. Thymic factor X (TFX) as a biologically active extract. Ann Immunol 1975, 7, 97.
20. Eichler F, Krueger GR. Effects of non-specific immunostimulants on the infection and antigen expression in herpes virus 6 exposed human lymphoid cells. In Vivo 1994, 8, 565-575.
21. Pontiglia P, Orgier C, Follini D. Effect of treatment with thymostimulin (Tp1) on T and B cells lymphoprolipherative disorders. Blut 1983, 47, 153.
22. Tas MP, Simons PJ, Balm FJ, Dexhage HA. Depressed monocyte polarization and clustering of dendritic cells in patients with head and neck cancer. Cancer Immunol 1993, 36, 108-114.
23. Gieldanowski J, Lemmel EM, Blaszcyk B. The influence of thymus hormones on the NK cells activity. Arch Immunol Ther Exp Warsz 1987, 35, 57-61.
24. Molto LM, Carballido JA, Mazano L, Olivier C, Lapuerta M, Alvarez-Mon M. Thymostimulin enhances the natural cytotoxic activity of patients with transitional cell carcinoma of the bladder. Int J Immunopharmacol 1993, 15, 335-341.
25. Favalli C, Jezzi T, Mastino A, Rinaldi-Garaci C, Riccardi C. Modulation of natural killer activity by thymosin Alpha 1 and Interferon. Cancer Immunol Immunother 1985, 20, 189-192.
26. Low TLK, Goldstein AL. Thymosins: structures, function and therapeutic applications. Thymicts 1984, 6, 27-42.
27. Duchateua J, Servais G, Cooman R, Collet H, Bolla K. In vitro influence of thymopentin on proliferative responses and phytohemagglutinin. Induced interleukin production in normal human lymphocyte cultures. Surv Immunol Res 1985, 4, 116-124.
28. Gomes RM, Shinzato TO, Grynberg NF. Growth control of experimental tumour by syngeneic thymocyte extracts. Braz J Med Biol Res 1987, 20, 449-451.
29. Klein AS, Lang R, Eshel I, Sharabi Y, Shoham J. Modulation of immune response and tumour development in tumour bearing mice treated by the thymic factor thymostimulin. Cancer Res 1987, 47, 3351-3356.